Literature DB >> 21370476

Design, synthesis, and in vitro antifungal activity of 1-[(4-substituted-benzyl)methylamino]-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ols.

Rémi Guillon1, Fabrice Pagniez, Francis Giraud, Damien Crépin, Carine Picot, Marc Le Borgne, Florent Morio, Muriel Duflos, Cédric Logé, Patrice Le Pape.   

Abstract

As part of our studies focused on the design of 1-[((hetero)aryl- and piperidinylmethyl)amino]-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols as antifungal agents, we report the development of new extended benzylamine derivatives substituted at the para position by sulfonamide or retrosulfonamide groups linked to alkyl or aryl chains. These molecules have broad-spectrum antifungal activities not only against Candida spp., including fluconazole-resistant strains, but also against a filamentous species (A. fumigatus). Concerning fluconazole resistance, selected compounds exhibit the capacity to overcome CDR and ERG11 gene upregulation and to maintain antifungal activity despite a recognized critical CYP51 substitution in C. albicans isolates. Synthesis, investigation of the mechanism of action by sterol analysis in a C. albicans strain, and structure-activity relationships (SARs) are reported.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21370476     DOI: 10.1002/cmdc.201000530

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  2 in total

1.  Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.

Authors:  Rémi Guillon; Fabrice Pagniez; Carine Picot; Damien Hédou; Alain Tonnerre; Elizabeth Chosson; Muriel Duflos; Thierry Besson; Cédric Logé; Patrice Le Pape
Journal:  ACS Med Chem Lett       Date:  2013-01-17       Impact factor: 4.345

2.  1,2,3-Triazole-quinazolin-4(3H)-one conjugates: evolution of ergosterol inhibitor as anticandidal agent.

Authors:  Mir Mohammad Masood; Mohammad Irfan; Parvez Khan; Mohamed F Alajmi; Afzal Hussain; Jered Garrison; Md Tabish Rehman; Mohammad Abid
Journal:  RSC Adv       Date:  2018-11-27       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.